FUJIFILM CELLULAR DYNAMICS INC

Their core work

FUJIFILM Cellular Dynamics (FCDI) is a US-based industrial producer of human induced pluripotent stem cells (iPSCs) and iPSC-derived cell types — neurons, cardiomyocytes, hepatocytes and others — used by pharma and academic labs for drug discovery, toxicity testing and disease modelling. They manufacture research-grade and disease-specific iPSC lines at scale and supply them to consortia that need reproducible, human-relevant cellular models instead of animal data. Their H2020 role is to bring commercial iPSC supply, quality-controlled differentiation protocols and biobanking know-how into European drug safety and neurodegeneration projects. In short: they are the cell factory behind the experiments, not a discovery lab of their own.

What they specialise in

How they've shifted over time

All three H2020 engagements started in 2019, so a true historical evolution cannot be drawn from this dataset alone — the early/recent split is artificial. Across these contemporaneous projects, their contribution clusters tightly around iPSC supply and iPSC-derived cell applications, branching into three adjacent uses: biobanking (EBiSC2), neurotoxicity screening (NeuroDeRisk) and brain-barrier drug delivery (IM2PACT). The pattern suggests a deliberate European push in 2019 to position their iPSC platform as infrastructure for neuroscience and drug-safety research.

They are consolidating as Europe's go-to industrial supplier of human iPSC-derived cells for CNS drug discovery and safety pharmacology, and are an obvious partner for any consortium needing reproducible human cellular models.

How they like to work

FCDI joins exclusively as a participant, never as coordinator, and operates inside large multi-partner consortia (52 unique partners across just 3 projects implies ~20-partner IMI/RIA teams). They fit the profile of a specialist industrial partner who brings a specific product and capability rather than scientific leadership. Expect them to deliver cells, protocols and QC — not to run work packages on hypothesis-driven science.

Across 3 projects they connect with 52 distinct partners spanning 16 countries, with strong exposure to European pharma and academic neuroscience networks typical of IMI-style consortia. Their network is broad rather than deep — little evidence of repeated partnerships, more of a hub serving many different teams.

What sets them apart

FCDI is one of very few commercial organisations in the world that can deliver research-grade and disease-specific human iPSCs and differentiated cell types at scale, backed by Fujifilm's industrial resources. Most H2020 iPSC work is performed by academic labs producing lines in small batches; FCDI offers reproducibility, regulatory-friendly documentation and freedom-to-operate clarity. Partner with them when a project needs a consistent industrial cell supply — not another academic stem-cell group.

Highlights from their portfolio

• EBiSC2
  The sustainable European iPSC biobank — a strategic positioning for FCDI as the industrial partner inside Europe's reference stem-cell repository.
• IM2PACT
  Tackles the blood-brain barrier bottleneck in CNS drug development using iPSC-derived human cell models, a high-value application for their product line.
• NeuroDeRisk
  Extends iPSC use into preclinical neurotoxicity screening, aligning FCDI with pharma's push to replace animal testing with human cell models.